ABVC BioPharma (ABVC) Proxy Filing summary

Executive summary

• The 2026 annual shareholder meeting will be held virtually on March 26, 2026, to address director elections, auditor ratification, and an amendment to the equity incentive plan.

• Shareholders of record as of January 26, 2026, are entitled to vote, with each share granting one vote.

• The Board unanimously recommends voting in favor of all proposals and director nominees.

Voting matters and shareholder proposals

• Proposals include re-election of 11 director nominees, ratification of Simon & Edward, LLP as independent auditor for 2026, and a one-time increase in the equity incentive plan to 15% of outstanding shares.

• Voting is by proxy only; no voting will occur during the virtual meeting.

• A quorum requires at least 33.3% of votes entitled to be cast; plurality elects directors, and other proposals require more votes in favor than against.

Board of directors and corporate governance

• The Board consists of 11 directors, with nine non-management and several classified as independent under Nasdaq rules.

• Committees include Audit, Compensation, and Corporate Governance/Nominating, each composed of independent directors.

• Guidelines for director selection emphasize ethics, experience, and diversity.

• Board leadership is separated between CEO and Chairman, with the Board overseeing risk management.